Patient characteristics
tumor, Tumor, toxicity, intermediate-risk disease, stage T2a-T3b
TUMOR, TUMOR, DISEASE, PROSTATE, URETHRA
Available data, toxicity, patient reported outcome and PSA control were obtained for 33 patients included in the trial, of whom 9 were included in Phase I and 24 in Phase II. Patient median age was 71 (range: 55–83). 94% of the patients were stage T2a-T3b. Median PSA was 12.83 µg/l (range: 2.7–40.4 µg/l). 54.6% were high risk disease, 42.4% were intermediate risk, and 3% low risk. Median IPSS was 5 (range 0–24) and median prostate volume was 40 ml (range: 12.4–67 ml). The median number of DIN was 1 (range: 1–3) and their median volume was 1.96 ml (range: 0.37–4.20). With the aid of a rectal balloon spacer the median distance between the DIN and the rectum was 12.2 mm (range: 4–22.9 mm). The median distance between the DIN and the urethra was 7.6 mm (range: 3–16.9 mm).The median RT treatment duration was 19 days (range: 11–26 days). All patients were able to complete their treatments. Despite appropriate counseling 97% of the patients refused ADT; ADT was only administered to a patient with intermediate-risk disease for 6 months. Patient’s and tumor characteristics are described in Tumor and Treatment Characteristics